Mañas Ana, Glaría Luis, Peña Carmen, Sotoca Amalia, Lanzós Eduardo, Fernandez Castalia, Rivière Marc
Servicio de Oncologia Radioterapica, Hospital Universitario Doce de Octubre, Madrid, Spain.
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):935-40. doi: 10.1016/j.ijrobp.2005.09.016. Epub 2006 Jan 10.
To assess the impact of bladder instillations of hyaluronic acid (HA) on the prevalence of urinary tract infection (UTI) in patients receiving emergency radiotherapy for metastatic spinal cord compression.
Patients were recruited consecutively at one center and assigned to usual care (UC) (n = 34, mean age 62.2 years) or UC with once-weekly HA instillation (UC + HA) (Cystistat: 40 mg in 50 mL phosphate-buffered saline) (n = 37; mean age, 63.1 years). All patients had an indwelling catheter and received radiotherapy. UTI status was assessed at baseline and during hospitalization.
At baseline, patient groups were comparable, except for the prevalence of UTI at baseline, which was 11.8% and 0% in the UC and UC + HA patients, respectively (p = 0.0477). During hospitalization, 76.5% (vs. 11.8% at baseline, p < 0.0001) of the UC patients had a UTI compared with 13.5% (vs. 0% at baseline, p = 0.0541) of the UC + HA patients (p < 0.0001). Both groups were hospitalized for similar periods (19.8 days [UC] vs. 18.5 days, p = 0.4769) and received equivalent radiotherapy sessions (4.6 [UC] vs. 5.8 sessions, p = 0.2368).
Patients receiving UC + HA had a 5.7-fold decrease in UTI prevalence over the hospitalization period compared to UC patients, suggesting that bladder instillations of HA effectively prevent UTI in patients with indwelling catheters receiving radiotherapy for nerve compression.
评估透明质酸(HA)膀胱灌注对接受转移性脊髓压迫急诊放疗患者尿路感染(UTI)患病率的影响。
在一个中心连续招募患者,将其分为常规护理(UC)组(n = 34,平均年龄62.2岁)或每周一次HA灌注的常规护理组(UC + HA)(Cystistat:40 mg溶于50 mL磷酸盐缓冲盐水中)(n = 37;平均年龄63.1岁)。所有患者均留置导尿管并接受放疗。在基线和住院期间评估UTI状态。
在基线时,除了基线时UTI的患病率外,患者组具有可比性,UC组和UC + HA组患者的基线UTI患病率分别为11.8%和0%(p = 0.0477)。住院期间,UC组76.5%的患者发生UTI(与基线时的11.8%相比,p < 0.0001),而UC + HA组为13.5%(与基线时的0%相比,p = 0.0541)(p < 0.0001)。两组的住院时间相似(UC组为19.8天,对照组为18.5天,p = 0.4769),接受的放疗疗程相当(UC组为4.6个疗程,对照组为5.8个疗程,p = 0.2368)。
与UC组患者相比,接受UC + HA治疗的患者在住院期间UTI患病率降低了5.7倍,这表明HA膀胱灌注可有效预防接受神经压迫放疗的留置导尿管患者发生UTI。